0001104659-23-084965.txt : 20230728 0001104659-23-084965.hdr.sgml : 20230728 20230728060820 ACCESSION NUMBER: 0001104659-23-084965 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230727 FILED AS OF DATE: 20230728 DATE AS OF CHANGE: 20230728 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kim Na Yeon CENTRAL INDEX KEY: 0001794779 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37809 FILM NUMBER: 231120080 MAIL ADDRESS: STREET 1: C/O NEUROBO PHARMACEUTICALS, INC. STREET 2: 177 HUNTINGTON AVENUE, SUITE 1700 CITY: BOSTON STATE: MA ZIP: 02115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NeuroBo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001638287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472389984 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BERKELEY ST. STREET 2: FL 19 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (857) 702-9600 MAIL ADDRESS: STREET 1: 200 BERKELEY ST. STREET 2: FL 19 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Gemphire Therapeutics Inc. DATE OF NAME CHANGE: 20150331 4 1 tm2321997-6_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-07-27 0 0001638287 NeuroBo Pharmaceuticals, Inc. NRBO 0001794779 Kim Na Yeon C/O NEUROBO PHARMACEUTICALS, INC. 200 BERKELEY STREET, OFFICE 19TH FLOOR BOSTON MA 02116 1 0 1 0 0 Common Stock 2023-07-27 4 A 0 87500 0 A 88959 D Common Stock 2023-07-27 4 A 0 12500 0 A 101459 D Common Stock 4671 I Held by E&Investment Inc. Common Stock 96351 I Held by The E&Healthcare Investment Fund II Common Stock 37373 I Held by The E&Healthcare Investment Fund No. 6 Common Stock 62159 I Held by The E&Healthcare Investment Fund No. 7 Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service. The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock. Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. /s/ Phillip D. Torrence, by Power of Attorney 2023-07-28